Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies (IM-TMI)
A Phase I Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Sponsor: University of Illinois at Chicago
Listed as NCT00988013, this NA trial focuses on Acute Leukemia and Acute Myeloid Leukemia and remains completed. Sponsored by University of Illinois at Chicago, it has been updated 10 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Sep 2021 — Dec 2022 [monthly]
Completed NA
Phase: PHASE1 → NA
▶ Show 5 earlier versions
-
Feb 2021 — Sep 2021 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Jan 2021 — Feb 2021 [monthly]
Unknown Status PHASE1
-
Nov 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
First recorded
Sep 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Illinois at Chicago
For direct contact, visit the study record on ClinicalTrials.gov .